Document Detail


Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.
MedLine Citation:
PMID:  15771759     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To study the effects of infliximab on pregnancy and foetal outcome. METHODS: We conducted a retrospective chart review of women with Crohn's disease treated intentionally with infliximab during pregnancy. The primary outcome measure was the occurrence of congenital malformations. Secondary outcome measures were the rate of premature birth, low-birth weight, small for gestational age infants, intrauterine growth retardation and caesarean section. RESULTS: Ten women were identified. Eight women received maintenance infliximab infusions throughout their pregnancy and two women received their initial infliximab infusions during pregnancy. All 10 pregnancies ended in live births. No infants had congenital malformations, intrauterine growth retardation or small for gestational age parameters. Three infants were premature and one had low-birth weight. Eight women had a caesarean section. CONCLUSIONS: This is the first reported series of intentional infliximab use throughout pregnancy. These data, combined with other studies of inadvertent use of infliximab during pregnancy, suggest that the benefits of infliximab in achieving response and maintaining remission in mothers with Crohn's disease may outweigh the risk to the foetus of exposure to the drug. Further prospective data collection will be helpful to confirm these findings.
Authors:
U Mahadevan; S Kane; W J Sandborn; R D Cohen; K Hanson; J P Terdiman; D G Binion
Related Documents :
11014379 - Respiratory bronchiolitis: an unusual cause of pulmonary infiltrates in a pregnant woman.
15987629 - Pregnancy in women with congenital heart disease.
14517489 - Factor viii and von willebrand factor changes during normal pregnancy and puerperium.
678479 - Leucocyte alkaline phosphatase activity during high risk pregnancies.
18293689 - Pregnancy and inflammatory bowel disease: a prospective case-control study.
20733499 - Myasthenia gravis and pregnancy: anaesthetic management--a series of cases.
14587909 - Developmental toxicity of in ovo exposure to polychlorinated biphenyls: ii. effects of ...
12765319 - The effects of asthma on pregnancy and perinatal outcomes.
25300499 - Does knowledge of danger signs of pregnancy predict birth preparedness? a critique of t...
Publication Detail:
Type:  Journal Article; Multicenter Study; Review    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  21     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-03-17     Completed Date:  2005-06-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  733-8     Citation Subset:  IM    
Affiliation:
Division of Gastroenterology, Department of Medicine, University of California San Francisco, CA 94115, USA. umamah@itsa.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced / etiology
Adult
Antibodies, Monoclonal / adverse effects*
Crohn Disease / drug therapy*
Female
Fetal Growth Retardation / chemically induced
Gastrointestinal Agents / adverse effects*
Gestational Age
Humans
Infant, Newborn
Infant, Small for Gestational Age
Middle Aged
Pregnancy
Pregnancy Complications / drug therapy*
Pregnancy Outcome*
Retrospective Studies
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Gastrointestinal Agents; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal ele...
Next Document:  A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive o...